Biotech company Acuitas Therapeutics and Germany-based CureVac have settled Acuitas' lawsuit demanding credit for inventions ...

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants ...

CureVac and Acuitas Therapeutics have settled their COVID-19 vaccine dispute. According to a filing, submitted April 25, 2024 ...

A healthcare company based out of Maryland saw its shares skyrocket on Tuesday after it was announced that David Lazar is going to invest $ million in preferred stock and take over as the company ...

Beyond a doubt, Vancouver-based Acuitas Therapeutics, Inc. punches above its weight. It is the global leader in developing lipid nanoparticle (LNP) delivery technology for nucleic acid ...

Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for ...

CureVac continues to advance its clinical development programs in prophylactic vaccines in collaboration with GSK. All currently tested candidates apply modified mRNA and are based on CureVac’s ...

VERVE-101 uses LNP technology licensed from privately held Acuitas Therapeutics, and according to Minter may incorporate an ionizable lipid shown to induce transient liver enzyme elevations in ...

On October 31, 2023, the Company and Acuitas Capital entered into a Fifth Amendment to the Master Note Purchase Agreement, as ...

Benzinga - by Vandana Singh, Benzinga Editor. Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV (NASDAQ:CVAC) have settled Acuitas’ lawsuit over credit for inventions tied to ...